Business Context and Reporting Period
This Form 8-K is a current report filed by Cerecor Inc. on August 29, 2016. The filing discloses the initiation of a second Phase 2 clinical trial for the company's investigational drug, CERC-501. Note: The request metadata referenced "Avalo Therapeutics, Inc.," but the filing text explicitly identifies the registrant as Cerecor Inc.
Key Financial Metrics
This filing is a regulatory disclosure regarding a clinical trial milestone and does not contain financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The material event reported is the enrollment of the first subject in a new Phase 2 clinical trial for CERC-501. This represents a progression in the company's clinical development pipeline rather than a financial change.
Outlook, Management Commentary, and Risks
- Clinical Trial Details: The study is titled "Does CERC-501 Attenuate Stress-Related Smoking Lapse?" and is a collaborative effort with Dr. Sherry McKee from Yale University.
- Funding: The trial is supported by funding from the National Institutes of Health (NIH).
- Study Design: It is a double-blind, placebo-controlled, crossover study.
- Primary Objective: To evaluate if CERC-501 increases the ability to resist smoking and reduces subsequent smoking following overnight nicotine deprivation and personalized stress imagery in heavy smokers.
- Regulatory Status: The information is furnished under Regulation FD and is not deemed "filed" for purposes of Section 18 of the Exchange Act.
Investor Verification Checklist
- Verify the specific enrollment targets and timeline for the CERC-501 Phase 2 trial.
- Confirm the extent of NIH funding and any associated grant obligations.
- Review the company's cash runway and burn rate in subsequent filings (e.g., 10-Q or 10-K) as this 8-K contains no financial data.
- Monitor future updates on the primary endpoint results regarding smoking lapse attenuation.